西妥昔单抗联合FOLFOX化疗治疗转移性结直肠癌的临床研究

Clinical Research of Cetuximab Combined with FOLFOX Chemotherapy for Treating Metastatic Colorectal Cancer

目的观察西妥昔单抗联合FOLFOX化疗治疗转移性结直肠癌(MCRC)的近期疗效及不良反应。方法 48例确诊为MCRC患者为研究对象。西妥昔单抗每周给药,首剂负荷量为400mg·m- 2,维持量为250mg·m- 2;联合方案:奥沙利铂85mg·m- 2+5-氟尿嘧啶600mg·m- 2+亚叶酸钙200mg·m- 2,2周为一个周期。完成两个周期的化疗以后,评价疗效,观察中位至疾病进展时间和不良反应。结果完全缓解0例,部分缓解39例,疾病稳定9例,疾病进展0例,总有效率81.3%,疾病控制率100.0%,中位至疾病进展时间是9个月。不良反应主要为Ⅰ~Ⅱ级。结论西妥昔单抗联合FOLFOX的化疗方案治疗MCRC可获得较高有效率,延长了疾病进展时间,改善了患者的生活质量,值得临床推广应用。

OBJECTIVE To observe the recent efficacy and toxicity of cetuximab combined FOLFOX chemotherapy for treating metastatic colorectal cancer (MCRC).METHODS Forty-eight cases of patients with MCRC were studied.Cetuximab was administered weekly,the first loading dose was 400 mg·m-2,maintenance dose was 250 mg·m-2.Joint programme: oxaliplatin 85 mg·m-2+5-fluorouracil 600 mg·m-2+leucovorin 200 mg·m-2,2 weeks as a cycle.After 2 cycles of chemotherapy,recent efficacy was evaluated,the TTP and toxicity were observed.RESULTS CR 0 case,PR 39 cases,SD 9 cases,PD 0 case,the total effective rate was 81.3%,the disease control rate was 100.0%,the TTP was 9 months.The toxicity was mainly Ⅰ-Ⅱ grade.CONCLUSION Cetuximab combined with FOLFOX chemotherapy for treating MCRC can get higher efficiency,longer TTP and can improve the quality of patient’s life.It is worthy of clinical application.